Providing independent clinical excellence since 2005
The most effective path to reducing visceral fat without medication is not just to “eat less.” It’s to build more muscle, eat smarter, and track your progress. In this blog, which also forms one of the chapters of an ebook, I outline the programme and tools our patients use in our cardiometabolic clinic.
Traditional health improvement plans assume everyone responds the same way. Real life tells us otherwise. N-of-1 explains how to use a personalised, precision-medicine approach to reduce visceral fat, stabilise metabolism and rebuild long-term health. Through weekly reflections, practical tools and small self-experiments, the book guides you to uncover what truly works for you — not for the average patient, but for your own unique physiology.
Some small studies show lower T3 inside fat tissue in people with obesity. This doesn’t mean systemic hypothyroidism — it simply suggests inflammation may reduce local T3 activation. Raised visceral fat quietly disrupts thyroid chemistry, increasing reverse T3 and lowering active T3 inside tissues.
MASLD is a silent but important marker of metabolic health and another consequence of raised Visceral Adipose Tissue (VAT). Although often discovered by chance, it carries significant implications for both liver and cardiovascular wellbeing. Through caloric restriction, physical activity, improved nutrition, and early intervention, MASLD can usualy be stabilised or reversed — protecting not just the liver, but the heart as well.
Small dense LDL (sdLDL) is the most harmful form of “bad cholesterol.” It forms when the liver overproduces VLDL — often driven by visceral fat and high insulin levels. Visceral fat sits deep around the organs and feeds directly into the liver, causing early metabolic disruption long before blood tests detect it.
Visceral fat (VAT) is the dangerous, hidden fat stored around your organs that accumulates. when caloric intake exceeds energy demand, since glucose and fats that can’t be used gets stored as adipose tissue. This blog explains how ageing, muscle loss, glucose spikes and genetic factors all drive VAT accumulation — and how reversing the cycle requires restoring mitochondrial health, increasing muscle mass, and in many people, by reducing glycaemic overload.
Carbohydrate Sensitive Phenotype (CSP) is not a diagnosis of diabetes or obesity. Rather, it’s a biologically driven pattern of visceral fat accumulation and carbohydrate intolerance which is highly prevalent in those with a raised waist-to-height ratio (WHtR > 0.5), triggered by aging, Western-style diet and lifestyle. More importantly, CSP gives individuals a name for their experience—one that invites support instead of judgement, and allows them to engage with food and health choices free from social shame.
If you’re taking GLP-1 mimetics like Mounjaro, Ozempic, or Wegovy, you’re receiving a legitimate, medically prescribed therapy. Just like someone with asthma carries an inhaler, or a diabetic uses insulin, there’s no shame in needing a jab to support your metabolic health. Whether you are travelling or attending a hospitality event, here are some tips on how to navigate these new waters.
For patients with CKD 3b, a high-protein diet may accelerate renal decline and should be avoided. However, metabolic improvement via a moderate low-carbohydrate diet with controlled protein intake (~0.8 g/kg/day) and unsaturated fats is both feasible and safe when guided appropriately. Creatinine changes should be interpreted carefully in the context of diet, and dietary interventions should be closely monitored.
Adipose tissue—particularly visceral adipose tissue (VAT)—is not merely a passive energy store. It is metabolically active and pro-inflammatory, secreting cytokines and adipokines that drive systemic inflammation. It is therefore plausible that reducing VAT may alleviate joint pain by lowering inflammatory signalling, not just mechanical stress.
Traditional upper limits for ALT (often ≤55 U/L in UK labs) were derived decades ago, before the epidemic of obesity and steatosis. Current evidence suggests these ranges are too high — and that values above 30 U/L may already indicate liver injury in people with metabolic risk. The British Society of Gastroenterology (BSG) guidelines emphasise that a result within the “normal range” may not be reassuring if the patient is metabolically high-risk
An article by Dr Edward Leatham, Consultant Cardiologist © 2025 E.Leatham While everyone might think the term ‘VAT’ stands for value added tax, we all need to recognise this new health term, as it is shaping up to be a critical risk […]